Ynno Med is a drug R&D company committed to addressing the unmet clinical needs for new antimicrobial agents to combat antimicrobial resistance. Our goal is to design, develop, and distribute first-in-class (FIC) antimicrobial medicines that effectively treat current antibiotic-resistant bacterial infections and suppress the emergence of new resistance. We accelerate our drug development process using our in-house AI-driven drug optimization platform, which is also available for providing drug design and discovery services.